Company intelligence / Profile preview

BioMedcore

Windsor, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

BioMedcore developed the Zgraft platform, a proprietary diagnostic technology that models a patient’s cancer outside the body, enabling oncologists to predict patient-specific response to chemotherapy within two weeks of diagnosis. This technology was aimed at enabling tailored treatment decisions for cancer patients, particularly in late-stage disease, but there is no record of commercialization for direct clinical use in patients; it was commercialized as a preclinical research tool in collaboration with Singapore’s A*STAR and further evolved to support additional patent filings.

Therapeutic areas: Oncology
Modalities: DiagnosticsPlatform Technology (Zgraft)
Industry: Molecular Diagnostics

Partnerships

Agency for Science, Technology and Research (A*STAR), SingaporeSuntrition

Beyond the preview

Go deeper on BioMedcore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMedcore.

Explore the full profile